Kristen, A., Biener, M., Hegenbart, U., Hardt, S., Schnabel, P. A., Röcken, C., . . . Giannitsis, E. (2014). Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. International journal of cardiology, 176(3), . https://doi.org/10.1016/j.ijcard.2014.07.106
Chicago-Zitierstil (17. Ausg.)Kristen, Arnt, Moritz Biener, Ute Hegenbart, Stefan Hardt, Philipp Albert Schnabel, Christoph Röcken, Stefan Schönland, Hugo Katus, und Evangelos Giannitsis. "Evaluation of the Clinical Use of Midregional Pro-atrial Natriuretic Peptide (MR-proANP) in Comparison to N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for Risk Stratification in Patients with Light-chain Amyloidosis." International Journal of Cardiology 176, no. 3 (2014). https://doi.org/10.1016/j.ijcard.2014.07.106.
MLA-Zitierstil (9. Ausg.)Kristen, Arnt, et al. "Evaluation of the Clinical Use of Midregional Pro-atrial Natriuretic Peptide (MR-proANP) in Comparison to N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for Risk Stratification in Patients with Light-chain Amyloidosis." International Journal of Cardiology, vol. 176, no. 3, 2014, https://doi.org/10.1016/j.ijcard.2014.07.106.